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Abstract  38 
Neutralizing antibody (nAb) function provides a foundation for vaccine and therapeutic 39 
efficacy(1-3). Utilising a robust in vitro Ebola Virus (EBOV) pseudo-particle infection assay 40 
together with a well-defined set of solid phase assays we describe a wide spectrum of antibody 41 
responses in a cohort of healthy Ebola survivors from the Sierra Leone outbreak (2013-2016). 42 
Pseudo-particle virus (PPV) nAbs correlated with total anti-EBOV reactivity and nAbs against 43 
live EBOV. Variant EBOV glycoprotein (EBOV-GP) (1995 and 2014 strains) were found to 44 
be similarly neutralized. During longitudinal follow up antibody responses increased rapidly 45 
in a “decay-stimulation-decay” pattern suggesting de novo EBOV antigenic restimulation after 46 
recovery. A pharmacodynamic model of antibody reactivity identified a decay half-life of 77–47 
100 days and a doubling-time of 46–86 days in a high proportion of survivors. The highest 48 
antibody reactivity was induced at around 200 days post-cure. The model suggests that EBOV 49 
antibody reactivity declines over 0.5-2 years post-cure. In a high proportion of healthy 50 
survivors’ antibody responses undergo rapid re-stimulation. Vigilant follow up of survivors 51 
and possible elective de-novo antigenic stimulation by vaccine immunisation needs 52 
consideration to prevent EBOV viral recrudescence in recovering individuals to mitigate the 53 






Limited Ebola virus (EBOV) outbreaks have been recorded since 1976(1). The much larger 58 
2013–2016 West African epidemic (28,610 cases), and the ongoing 2018 Eastern Zaire 59 
outbreak (3,188 cases as of September 2019) (https://www.who.int/emergencies/ 60 
diseases/Ebola/drc-2019) in the Democratic Republic of Congo proved to be more extensive. 61 
The larger outbreaks have indicated viral persistence in some individuals with the potential for 62 
subsequent transmission of virus(2). Due to limited EBOV outbreaks the understanding of 63 
natural induced immune responses is limited and vaccine induced correlates stem from animal 64 
models(3). These models have indicated that total IgG binding antibody levels can correlate 65 
with protection along with neutralising antibody (nAb) responses, which can typically be low. 66 
Human outbreaks have provided valuable information regarding EBOV therapeutic(4) and 67 
vaccine intervention strategies(5-7). More recently nAbs have been the focus of therapeutic 68 
development(8-12) where a cocktail of monoclonal antibodies (mAbs) was administered during 69 
the 2013-2016 outbreak(12-13) and with evidence of efficacy in trials conducted in the DRC(14). 70 
In early 2015, two related studies [Ebola-Tx(15) and Ebola-CP(16)] were established where 71 
apparently health EBOV survivors were recruited with the intent of using their convalescent 72 
plasma (CP) to treat disease (4,16-17). We used CP from the donors of the Ebola-CP study 73 
(Supplementary Table 1a) where samples were collected longitudinally (30-500 days) to 74 
better ascertain how nAb responses evolve. Such responses have previously been studied both 75 
in humans and primates with broad nAb activity(4,18-20).  76 
 77 
A range of solid-phase enzyme-linked immunoassays (EIAs) based on Mayinga EBOV strain 78 
recombinant antigen were initially developed to characterise antibody responses in potential 79 
donors of therapeutic CP(21). To circumvent the complexity of utilising replication competent 80 
EBOV in expanding the analysis to characterise neutralisation responses we utilised single-81 
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round infectious pseudo-particle viruses (PVV) as described (see Methods). Optimal virus 82 
production and infectivity was identified by limiting dilution of EBOV14-GP expressing 83 
plasmid (Extended Data Fig. 1a). GPs from three EBOV strains were used for PPV 84 
production; the early 2014 epidemic strain (pEBOV14-GP) (Accession: KP096421)(22), a 85 
modified variant (pEBOV14m-GP) comprising of mutations appearing early during the 86 
outbreak (Fig. 1b, Supplementary Table 2) and the 1995 Kikwit strain (pEBOV95-GP) 87 
(Accession: KC242799)(23) represented in the vaccine administered latterly in the 2013-2016 88 
outbreak. EBOV14-GP PPV demonstrated consistently lower infectivity (Fig. 1a), presumably 89 
attributed to the T544I amino acid previously described(24). The A82V alteration (pEBOV14m-90 
GP) introduced early in the epidemic and subsequently found in more than 90% of the 2013-91 
2016 isolates was also reported to have a higher infectivity profile(25). Interestingly, this 92 
genotype did not associate with altered disease pathogenicity in a primate model system(26). 93 
 94 
We utilized the above PPV infection assay in order to quantify nAb responses in CP donors 95 
(using limiting dilutions of plasma). In order to determine non-specific neutralisation effects 96 
we tested EBOV antibody negative plasmas (n=6) to find the range of non-specific inhibition 97 
(Extended Data Fig. 1b) and CPs with results subsequently falling within this range were 98 
considered lacking neutralizing potential. Furthermore, PPV expressing the HIV-1 envelope 99 
protein were used to test a high titre EBOV antibody positive plasma that was within the non-100 
neutralizing range (Extended Data Fig. 1b). The WHO Anti-EBOV Convalescent Plasma 101 
International Reference Panel (NIBSC 16/344) was used to demonstrate the neutralizing 102 
potential of EBOV antibody-positive sera (IC50 range: 6.33-7.01 log2 plasma dilution) 103 
(Extended Data Fig. 1c) which was found to be comparable to the values previously 104 
published(27). The robustness of the assay was tested using EBOV survivors’ plasma to inhibit 105 
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the three PPV strains produced, each in different batches with the assay repeated in two 106 
biologically independent experiments (Extended Data Fig. 1d).  107 
 108 
CPs (n=52) demonstrated a wide range of neutralisation potential (Supplementary Table 1b-109 
d), however had comparable profiles when assayed using all three EBOV PPV strains 110 
(Extended Data Fig. 2a-c). Half-maximal (IC50) and seventy percent (IC70) inhibitory 111 
concentrations determined correlated (Extended Data Fig. 3). Within this cohort no 112 
differences in neutralizing titres were observed between the three virus strains (Fig 1c, 113 
Extended Data Fig. 1e). pEBOV14-GP PPVs, demonstrating the lower infectivity profile 114 
(Fig. 1a), did not differ from the pEBOV95-GP strain isolated twenty years earlier, or the 115 
pEBOV14m-GP strain carrying early epidemic mutations including the A82V variant 116 
associated with higher infectivity. However, individual CPs having high IC50 and IC70 values 117 
against one virus strain did not necessarily neutralize the other two (Fig. 1d and Extended 118 
Data Fig. 1f), potentially highlighting epitope diversity amongst individual participants as well 119 
as virus strains. A subset of donor CPs (n=5) with sequential samplings (totalling n=30) 120 
(Supplementary Table 1e) were assayed against the replication competent EBOV (RCE) 121 
Makona 2014 isolate. A significant correlation between the two neutralisation platforms was 122 
shown (Fig. 1e and Extended Data Fig. 1g) (r=0.52, p<0.0001). In addition, our neutralisation 123 
data demonstrated a similarly significant correlation with total anti-EBOV reactivity measured 124 
using the double antigen bridging assay (DABA) (Fig. 1f) (r= 0.50, p<0.0001, IC50) and 125 
(Extended Data Fig. 1h) (r= 0.55, p<0.0001, IC70) corroborating previous results
(21) plus 126 
further validating our PPV neutralisation platform utilised here. The RCE and PPV assays 127 
demonstrated a stronger correlation when compared to neutralisation versus DABA. These two 128 
assays are targeting the same antibodies while DABA measures all antibodies and some 129 
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individuals would have differential responses, however, this was observed only in a very 130 
restricted number of donors. 131 
 132 
While nAbs are thought to develop later in infection(28) our data demonstrates their presence as 133 
early as 30 days post-cure, also supporting previous studies(29-30) indicating that nAb levels are 134 
detectable and persist following viral clearance. Cross-sectional analysis of antibody responses 135 
did not indicate notable changes in titres during the observation window (~500 days) (IC50 /Fig. 136 
2a and IC70 /Fig. 2b), comparable to the findings when fully replicating virus neutralisation 137 
was performed (Fig. 2c). However, within individuals often sustained decline was followed by 138 
a sharp antibody titre increase (Fig. 2a-c).  139 
 140 
The observed declines and subsequent rises in nAb levels identified in a portion of the study 141 
participants (Fig. 2a-c) indicates post-recovery de novo antigen stimulation. This was 142 
comprehensively demonstrated in Donor-CP-Pat-045 where antibody reactivity in all EIAs and 143 
including nAb initially decreased over a 45-day period (sampled six months post-recovery) 144 
prior to a sudden boost in antibody responses over a 23 day period (Fig. 2d). It should be noted 145 
that all donors were tested for plasma EBOV RNA twice in Sierra Leone and shown to be 146 
aviraemic before discharge from Ebola Treatment Units. Furthermore, all samples received in 147 
the United Kingdom (UK) were subsequently re-tested upon arrival, providing evidence of no 148 
detectable viremia in the available samples taken in this observation period. Intriguingly, the 149 
increase in antibody reactivity was higher against EBOV95-GP than EBOV14-GP though 150 
participation in any vaccine study (where the immunogen would mimic the 1995 strain) was 151 
ruled out through self-reporting and later confirmed by the lead investigators of the two Ebola 152 




Following on from these observations Donor-CP-Pat-045 along with Donors-CP-Pat -018, -155 
019, -021 and -049 were further tested using an additional panel of Enzyme Immune Assays 156 
(targeting the EBOV GP, nucleoprotein (NP) and VP40 matrix protein) and where similar 157 
variations in antibody responses were demonstrated (Fig. 2e-f, Extended Data Fig. 4) 158 
indicating that antibody re-stimulation targeted viral antigens which are not present in current 159 
vaccines and not just GP alone. Furthermore, similar variations in antibody responses were 160 
observed when implementing an IgG capture assay as well as a competitive antibody binding 161 
immunoassay, both targeting GP (Extended Data Fig. 5). Donor-CP-Pat -019 and -021 162 
antibodies were also found to increase before subsequently decreasing. The increases in Donor-163 
CP-Pat-045 EBOV antibodies occurred between mid-December 2015 and mid-January 2016. 164 
Two cases of Ebola were reported mid-January 2016 in the northern districts although Sierra 165 
Leone had been declared ‘Ebola free’ in November 2015 166 
(https://www.theguardian.com/world/2015/sep/04/sierra-leone-village-in-quarantine-after-167 
ebola-death. These donors and a control group of donors who did not demonstrate late rises in 168 
nAb reactivity were interviewed. All denied any intercurrent illness, known exposure to Ebola 169 
cases or participation in EBOV vaccine studies. It should also be borne in mind that by 170 
definition these convalescent donors had to meet individually the Sierra Leone National Safe 171 
Blood criteria for fitness to donate blood. Furthermore, interview and physical examinations 172 
were undertaken at each attendance for plasmapheresis. Whilst re-exposure to EBOV cannot 173 
be excluded it is assumed that the increase in antibody reactivity represents de novo antigenic 174 
stimulation at immune privileged sites boosting immunity. EBOV presence and ongoing 175 
replication in such sites has been described as late clinical recrudescence and reporting of 176 




Given this high degree of intra-patient fluctuation in EBOV virus antibody responses we used 179 
the data available to develop compartmental population pharmacodynamic models to quantify 180 
antibody stimulation and decay trends in this cohort. The strong association between nAb and 181 
total antibody binding measured by DABA reactivity (Fig 1f and Extended Data Fig. 1h) 182 
enabled us to utilise the more replete DABA data set which incorporates extensive longitudinal 183 
time-points as described (Supplementary Table 1f) to perform model selection for stimulation 184 
and decay trends. The best fitting models for stimulation and decay were objectively identified. 185 
By comparison of the log-likelihood based AIC BIC metrics (see methods and 186 
Supplementary Table 3a-c) as a one compartment model with reduced stimulation at high 187 
antibody levels (Fig. 3a) and a two-compartment decay model with saturable recycling of 188 
antibody (Fig. 3b). The rate constant for stimulation for total antibody binding reactivity was 189 
found to be 0.03 day-1, equivalent to a doubling time of 23 days (Supplementary Table 4) 190 
whilst the decay model provided a variable antibody concentration dependent rate constant 191 
equivalent to 30 days at half the maximum antibody level measured (Supplementary Table 192 
4). The two best structural models as selected using the DABA data, were then fitted using the 193 
nAb titre values for the EBOV14-GP & EBOV95-GP strains and simulations performed (Fig. 194 
3e-h). The calculated stimulation rate constants for the virus strain variants were 0.067 day-1 195 
and 0.046 day-1, respectively, possibly reflecting variation in epitope targets. The calculated 196 
endogenous nAb decay rates were found to be similar for the different virus strains (0.025 day-197 
1/ EBOV14-GP and 0.025 day-1/ EBOV95-GP) and matching the results initially found while 198 
modelling DABA reactivity (population mean of 0.028 day-1) (Supplementary Table 4). 199 
Resultant concentration dependent half-lives at half maximal observed antibody levels were 200 
calculated to be 51 and 70 days for EBOV14-GP and EBOV95-GP, respectively. Interestingly, 201 
our findings are fully congruent with recent studies modelling endogenous antibody 202 
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metabolism(37). To our knowledge this is the first population model of antibody level dynamics 203 
in EBOV survivors.  204 
 205 
We next simulated the stimulation and decay profiles for 1000 EBOV survivors using the 206 
developed population models used (Fig. 3c-3h). The interquartile range of total antibody levels 207 
can be seen to vary widely for the simulated cohort when tracked longitudinally, indicating a 208 
wide-ranging array of doubling times/half-lives. The mean simulated doubling times were 209 
found to be 18.93 days [IQR: 11.68 -33.62], 10.36 days [IQR: 9.96-10.81] and 13.76 days 210 
[IQR: 9.52- 23.56], for total binding antibody, nAbs against EBOV14-GP and against 211 
EBOV95-GP respectively, indicating that overall EBOV14-GP was stimulated the fastest with 212 
the least variability, which is reasonable given this was the 2013-2016 epidemic strain. The 213 
median simulated endogenous decay half-lives were found to be 20.86 days [IQR:13.81-214 
42.81], 27.40 days [IQR:19.62-41.66] and 28.23 days [IQR:24.33-33.33], respectively, in-line 215 
with previous estimates of IgG half-life(37). 216 
 217 
Longitudinal analysis demonstrated increasing antibody reactivity in a high proportion of study 218 
participants, somewhere between 200 and 300 days, post-cure shown by DABA (Fig 2e) 219 
(Extended Data Fig. 6), blocking EIA (Fig. 2e) (Extended Data Fig. 4), IgG Capture and 220 
competitive EIA (Extended Data Fig. 5) as well as with antibody neutralisation measurements 221 
(Fig. 2d). This suggests that as antibody responses are waning antigen levels increase resulting 222 
in a boost to the residual primary antibody response. When comparing the lowest observed 223 
antibody titres after decline with the highest antibody titres following stimulation (prior to 224 
further de novo decline) we observe a statistical difference in antibody levels (n=18, p<0.0014) 225 
(Extended Data Fig. 7). We have simulated a typical decay-restimulation-decay profile based 226 
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on population median parameters and starting levels demonstrating a projected typical scenario 227 
in a substantial proportion of EBOV survivors. (Fig. 3i). 228 
 229 
Analyses of naturally occurring nAb responses in our EBOV CP donor cohort revealed a high 230 
degree of variation in strength and breadth of induced responses. Longitudinal analysis of B 231 
cell responses in EBOV infected individuals has revealed stark changes in immunoglobulin 232 
subclass switching, heightened alterations to hypermutations and naive B cell re-stimulations 233 
over time(38). Our results would indicate that EBOV antigen re-exposure will be contributing 234 
to these observed alterations in antibody phenotypes described. It is encouraging to describe 235 
strong neutralisation cross-reactivity between EBOV strains representing outbreaks 20 years 236 
apart. This provides confidence that antibody induced either through natural infection or via a 237 
vaccine should elicit protection covering future outbreaks. Our results indicate that EBOV 238 
evolution(39-40), albeit slow, may result in altered neutralizing potential thus loss of vaccine 239 
efficacy (Fig. 1c and Extended Data Fig. 1f). Furthermore, if CP possessing broadly 240 
neutralizing activity were to be used in therapeutic protocols then combining plasmas from 241 
several individuals may ensure a more successful outcome. The best option could be the 242 
preparation of a hyperimmune intravenous immunoglobulin blood product from a panel of 243 
donors rather than relying currently on the use of individually sourced components. The high 244 
frequency of de novo antigenic stimulation described within the cohort indicate a need for 245 
heightened surveillance of survivors to meet the potential clinical needs associated with virus 246 
recrudescence. Subclinical recrudescence may intensify the long-lasting post Ebola sequelae 247 
suffered by most EBOV survivors(41-42). The cohort of CP donors studied here however 248 
represents a highly selected group of healthy individuals, further chosen through the use of 249 
field testing to have plasma antibody to EBOV in the upper quartiles of serological 250 
reactivity(21). Therefore, they may represent convalescent individuals least likely to suffer viral 251 
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recrudescence. Occult virus persistence is therefore likely to be more frequent than previously 252 
predicted, supporting findings that virus persists at sequestered sites in some individuals(2,43). 253 
In a case study of an immunocompromised HIV-1 infected individual (CD4 cell count 46/μL) 254 
EBOV could be detected in semen two years after the individual was discharged from the 255 
treatment unit(37) further underlining the importance of immune-competence for EBOV 256 
clearance. A longer and more frequent sampling would provide a more accurate indication of 257 
the extend of Ab re-stimulation occurrence in these Ebola survivors. 258 
 259 
The calculated mean half-life at median antibody levels has allowed predictions of time taken 260 
to reach 95% depletion of any given level post antigenic stimulation and given the exponential 261 
decay rate we can predict that the duration of six half-life periods (~180 to 417 days) will result 262 
in depletion of antibody levels by >95%. As a result, protection of EBOV survivors from viral 263 
recrudescence mediated by acquired immunity is likely to be 0.5-2 years post-recovery unless 264 
boosted.  265 
 266 
Continued surveillance of EBOV survivors is warranted considering the frequency of sub-267 
clinical de-novo antigenic stimulation we have described. Vaccination could be considered to 268 
boost protective antibody responses in survivors. This would also have a particular role if 269 
EBOV survivors are to be considered as plasma donors for use in future anti-Ebola passive 270 
immunotherapy. 271 
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Figure legends  377 
Fig 1: EBOV GP HIV-1 pseudo-typed virus neutralisation assay.. (a) Virus produced in 10 378 
cm culture dishes (n=60), using 285 ng of pEBOV14-GP, pEBOV14m or pEBOV95 plasmids, 379 
the infectivity of virus from each plate assayed and plotted individually for the three virus 380 
strains produced (Data are presented as mean values of duplicate measurements. Kruskal-Wallis 381 
test was performed). (b) amino acid (aa) differences in the glycoproteins (yellow boxes) of the 382 
three virus isolates studied. The differences are found in the GP1 base (orange), GP1 head 383 
(blue), Glycan cap (purple), mainly in the Mucin like domain (green) and the fusion loop (red). 384 
The black bars above sequences indicate potential N-linked glycosylation site modifications. 385 
In pEBOV14m-GP the glycosylation at the 230 position site is lost. The colour code for the aa 386 
is indicated on the first line.  (c) Neutralisation potential of CPs against three virus strains 387 
(pEBOV14-GP/n=98, pEBOV95-GP/n=80 and pEBOV14m-GP/n=79) expressed in IC50 (Data 388 
are presented as mean values of duplicate measurements. Kruskal-Wallis test was performed). (d) 389 
delta-IC50 neutralisation titres between virus strains pairs by each post-cure study participant. 390 
(e) Positive association between PPV IC50 titres the live virus plaque reduction neutralisation 391 
test (PRNT). (f) Positive association between PPV IC50 neutralisation titres and the double 392 
antigen bridging assay (DABA).  393 
 394 
Fig.2: Convalescent neutralizing antibody titres. (a) nAb IC50, (b) nAb IC70 values against 395 
three PPV isolates; (EBOV14 (n=92), EBOV14m (n=70) and EBOV95 (n=76) followed over 396 
time. (c) nAb IC50 values against PRNT-EBOV14 (n=30) followed over time. In all three 397 
panels (2a, b and c) day 0 is defined as the day when virus PCR test became negative or when 398 
the individual was declared Ebola free and discharged from the Ebola Treatment Unit. 399 
Individual lines indicate individuals who has donated sequential plasma samples demonstrating 400 
non-canonical antibody titre variation. The black dotted lines are the 5-95 and 25-75 quartiles 401 
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and the red areas represent the 95% confidence intervals of the linear association (red solid 402 
line), that for PPV was calculated separately for each half of the observation period. (d) 403 
Longitudinal follow up of Donor-045. Longitudinal post-cure antibody variation of donor-045 404 
demonstrated by PPV neutralisation of EBOV14 (light blue) and EBOV95 (dark blue) strains 405 
overlaid with virus neutralisation using the RCE PRNT (orange in upper panel) or total 406 
antibodies measured by DABA (green in lower panel). (e-f) Blocking EIAs using RCE were 407 
carried out for the detection of antibody against the Nucleoprotein [NP] (brown squares), the 408 
viral matrix protein 40 [VP40] (purple squares) and the Glycoprotein [GP] (green squares) 409 
using longitudinal plasma samples from donor-045 (e) and from donor-049 (f). 410 
 411 
Fig. 3: Rates of EBOV antibody decay and recovery following the 2013-16 West Africa 412 
outbreak. (a) Schematic depicting the one compartment model for first order stimulation 413 
(based on a logistic growth model) and (b) schematic depiction of the two-compartment 414 







 percentile concentrations. Shaded bands indicate 95% CI of predicted percentiles. 416 
(c-d) total anti-EBOV reactivity as measured by DABA (e-f) neutralizing antibody titres 417 
against the EBOV14 virus strain and (g-h) neutralizing antibody titres against the EBOV95 418 
Kikwit strain. Percentiles are calculated stimulation/decay profiles from Monte Carlo 419 
simulations of a population of 1000 randomly sampled individuals. Shaded areas surrounding 420 
percentile trajectories indicate 0.05 and 0.95 confidence intervals. (i) Graphic illustration of the 421 
post-infection acquired immune responses, illustrating the virus antigen stimulation hypothesis 422 
extrapolated from simulation of median fitted parameter values from the selected models. It 423 
depicts the acute sharp increase post-infection and the slow decrease post-cure. The observation 424 
period during this study is highlighted, demonstrating the antibody reactivity increase after 425 
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what is predicted to be a new antigenic stimulation occurring below a threshold of antibody 426 
protection.  427 
 428 
METHODS 429 
Ebola survivor cohort  430 
Ebola virus disease survivors (N=115), previously described42 with certificates (issued by 431 
Ebola Treatment Centers on discharge) were recruited as potential donors through 34 Military 432 
Hospital, Freetown, and the Sierra Leone Association of Ebola Survivors as participants in the 433 
study ‘Convalescent plasma (CP) for early Ebola virus disease in Sierra Leone’. The study 434 
(ISRCTN13990511 & ACTR201602001355272) was approved by the Scientific Review 435 
Committee and Sierra Leone Ethics, authorised by the Pharmacy Board of Sierra Leone 436 
(PBSL/CTAN/MOHSCST001) and sponsored by the University of Liverpool.  437 
 438 
Volunteers were considered suitable to donate plasma if they tested negative for blood borne 439 
infections (hepatitis B, hepatitis C, HIV, malaria and syphilis), had had 2 documented negative 440 
EBOV PCR tests 72 hours apart, had no acute febrile illness and had no comorbidity, such as 441 
heart failure, to suggest they might be at increased risk of adverse events during apheresis. 442 
Patients were not excluded if they exhibited indications of post Ebola syndrome (PES) (for 443 
example: musculoskeletal pain, headache, ocular problems) although such complaints were 444 
noted and subsequently contributed to the characterisation of PES41-42, 44. The majority of the 445 
participants were male (n=82), their age ranging between 18 and 52 with a median of 27 years 446 
old. The females’ (n=32) age ranged between 18 and 42 with a median of 27 years 447 




For transfusion safety reasons donor identity numbers were not confidential to donors during 450 
the conduct of the study; for the avoidance of doubt, donor identity numbers have since been 451 
dissociated. All participants (n=115) were tested using DABA, blocking EIA and IgG capture 452 
immunoassays21. PPV antibody neutralisation assays were performed with a subset of 453 
participants not selected on any criteria other than sample availability (N=52). The 454 
compartmental population pharmacodynamics model was developed on the more replete 455 
DABA dataset using those participants with longitudinal data (n=51) (Supplementary Table 456 
1f). 457 
 458 
Cell culture  459 
HEK293T (ATCC® CRL-3216™) and TZM-bl45-49 cells are adherent cell-lines cultivated in 460 
Dulbecco’s modified eagle medium (Invitrogen: 12491-023), supplemented with 10% heat-461 
treated foetal bovine serum (FBS) (Sigma: F7524), 2mM/ml L-glutamine (Invitrogen: 462 
25030024), 100 U/ml penicillin (Invitrogen: 15140148) and 100 mg/ml streptomycin 463 
(Invitrogen: 15140148), referred to as complete DMEM (Thermofisher: 12491023). Cells were 464 
grown in a humidified atmosphere at 37oC and 5% CO2. Vero E6 cells (ECACC: 85020206) 465 
were grown in VP-SFM (Therno-Fisher: 11681-020). 466 
 467 
EBOV PPV construct design  468 
Three viral strain glycoprotein genes were cloned into pCDNA3.1 produced by GeneArt using 469 
gene synthesis. A 2014 isolate (KP096421)22, a variant carrying the A82V, T230A, I371V, 470 
P375T, and T544I (Fig. 1b) identified by analysis of sequenced EBOV strains between March-471 
August 201439 and the AY354458 1995 Kikwit isolate50. The later been used in ring 472 




EBOV PPV production 475 
We chose to utilise the HIV-1 SG3 ΔEnv and EBOV-GP expression plasmids, co-transfected 476 
into HEK293T cells, to generate infectious pseudo-particle virus (PPV) stocks47,51-52. The 477 
EBOV-GP-pseudo-typed lentiviral system generates single-cycle infectious viral particles. 478 
HEK293T cells were plated at a density of 1.2x106 in a 10 cm diameter tissue culture dish 479 
(Corning: 430167) in 8ml of complete DMEM and incubated overnight. The cells were 480 
transfected with 2µg of pSG3Δenv along with 0.285µg of a plasmid expressing EBOV-GP 481 
using a cationic polymer transfection reagent (Polyethylenimine/polysciences: 23966-2), in the 482 
presence of OptiMEM (Invitrogen: 31985-070). OptiMEM was replaced 6 hrs post transfection 483 
with 8 ml of complete DMEM. 72 hours post-transfection supernatant containing the generated 484 
stock of single-cycle infectious EBOV-GP pseudo-typed virus particles were harvested, passed 485 
through a 0.45 µM filter and stored in aliquots at −80 °C. EBOV-GP plasmid (285 ng /10 cm 486 
culture dishes) was used to produce a large virus stock that was tested for infectivity (Fig. 1a) 487 
then pooled, aliquoted and stored under -80 °C. 488 
 489 
EBOV PPV infection 490 
EBOV infectivity was determined through infection of TZM-bl cell lines where luciferase 491 
activity (expressed from LTR promoter) is under the control of Tat expressed from the HIV-1 492 
backbone. 100 µl of EBOV-GP virus was used to infect 1.5x104 TZM-bl/ cells/ well for 6 hrs 493 
in a white 96 well plate (Corning: CLS3595). Following infection 150µl/well DMEM complete 494 
was added to the cells. 48 hrs post infection, media was discarded from the wells, cells were 495 
washed with phosphate buffered saline (PBS, Thernofisher:12899712), lysed with 30 µl Cell 496 
lysis buffer (Promega: E1531) and luciferase activity was determined by luciferase assay 497 
(Promega: E1501) using a BMGLabtech FluoroStar Omega luminometer. Negative controls 498 
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included pseudo-typed virus bearing no glycoproteins and TZM-bl cells alone which routinely 499 
resulted in luminescence of between 3000-7000 Relative Light Units (RLU). 500 
 501 
EBOV PPV neutralisation  502 
A panel of plasma samples (n= 52) from Ebola convalescent plasma and healthy blood donors 503 
(n= 6) were heat treated at 56oC for 30 min and centrifuged for 15 mins, 13,000 RPM, aliquots 504 
were then stored at −80 °C. Plasma samples were serially diluted ½ with complete DMEM; 13 505 
µl plasma dilution was incubated with 200 µl EBOV-GP PPV for 1 hr at RT. 100 µl of 506 
virus/plasma dilution was used to infect TZM-bl cells as described previously. Luciferase 507 
activity readings of neutralised virus were analysed i) by considering 0% inhibition as the 508 
infection values of the virus in the absence of convalescent plasma included in each experiment, 509 
ii) by considering 0% inhibition as the infection values of two consecutive high dilutions not 510 
inhibiting virus entry. Both methods produced highly correlated results (Extended data Fig. 511 
2d) and the latter was used. The neutralisation potential of a CP was represented as the plasma 512 
dilution that reduced viral infectivity by 50% (IC50) or by 70% (IC70). 513 
 514 
Enzyme Immune Assays  515 
HIV-1-P24 capsid: Samples were diluted in 0.1% Empigen (Sigma: 30326)/ TBS prior to 516 
performing the ELISA assay (Fisher: 10167481). The p24 assays were conducted using the 517 
Aalto Bio Reagents Ltd protocol and recombinant p24 standard, p24 coating antibody 518 
(polyclonal sheep anti-HIV-1-p24 gag, Aalto Bio Reagents Ltd, D7320), secondary conjugate 519 
(alkaline phosphatase conjugate of mouse monoclonal anti-HIV-1-p24, Boehringer Mannheim, 520 
1089-161) and ELISA light assay buffer. Plates were incubated 30 min at RT. prior to 521 




Double antigen bridging assay (DABA): Measured EBOV GP targeting antibody present in 524 
Ebola survivor CP samples. EBOV GP antigen, Mayinga Zaire EBOV strain (IBT Bioservices: 525 
0501‐016) was pre-coated onto the ‘solid phase’, whilst a second antigen conjugated to 526 
horseradish peroxidase (HRP) acted as the detector binding to EBOV antibody captured on the 527 
solid-phase antigen in the first incubation step. Antibody reactivity was expressed as arbitrary 528 
units/ml (au/ml) as compared to a standard; five reactive donor samples that were pooled and 529 
attributed 1000 au/ml21.  530 
 531 
Blocking EIA: Antibody levels in CP to EBOV GP (glycoprotein), VP40, NP (nucleoprotein) 532 
were determined by blocking of the binding of specific rabbit EBOV anti-peptide (GP, VP40, 533 
NP) antibodies (IBT Bioservices) to EBOV Makona virion coated microplates. Microplate 534 
wells were coated with 10,000-fold dilution of concentrated Ebola virions. EBOV patient CP 535 
and negative control CP dilutions (1/100) were reacted on virion coated microplates for 4-6 536 
hrs. CP dilutions were removed and plates were then reacted with EBOV anti-peptide 537 
antibodies. Bound rabbit antibodies were detected by species specific horseradish peroxidase 538 
conjugate (DAKO: P03991-2). Evidence of EBOV protein specific human antibodies in CP 539 
was determined by the blocking of the binding of the antipeptide antibody compared to the 540 
blocking of binding by the CP negative control. Results were expressed as a percentage of 541 
blocking of the CP negative control reactivity. 542 
 543 
IgG capture assay: IgG antibody present in CP was captured onto a solid phase coated with 544 
rabbit hyperimmune anti-human γ-Fc and interrogated in a second incubation with HRP-545 
conjugated EBOV GP as above. Reactivity expressed as binding ratios derived as sample 546 




Plaque Reduction Neutralization Test  549 
The wild type strain used for assays was EBOV Makona (GenBank accession number 550 
KJ660347)21, isolated from a female Guinean patient in March 2014 (virus provided to PHE 551 
Porton by Stephan Günther, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, 552 
Germany). The virus was propagated in Vero E6 cells and culture supernatant virions were 553 
concentrated by ultracentrifugation through a 20% glycerol cushion; pellets resuspended in 554 
sterile phosphate buffered saline at a titre of 109 focus forming units (FFU) per ml.  555 
 556 
Wild type virus neutralising antibody titre in CP was determined by reacting serial dilutions of 557 
CP with 100 FFU of EBOV virions for 1 hr at RT to allow antibody binding. EBOV virion CP 558 
mixture was adsorbed to Vero E6 monolayers for 1 hr and then overlaid with cell growth 559 
medium containing 1% (v/v) Avicel (Sigma-Aldrich). After 80-90 hrs EBOV foci were 560 
visualised by immunostaining with anti-VLP (Zaire EBOV) antibodies (IBT Bioservices). All 561 
work was undertaken under ACDP containment level 4 conditions. 562 
 563 
EBOV antibody decay and restimulation modelling  564 
Compartmental population analysis was performed to model the stimulation and decay of 565 
antibody levels. All modelling and simulations were performed using Pmetrics version 1.453. 566 
Within R version 3.2.254. Antibody levels of EBOV survivors were sampled a different number 567 
of instances, at varying intervals post convalescence due to follow-up adherence limitations in 568 
the field. Different parts of decay/stimulation profiles were therefore captured with only a few 569 
instances of contiguous decay-stimulation or stimulation-decay profiles being captured. 570 
Stimulation and decay data were therefore modelled separately to most efficiently use the data. 571 
Antibody stimulation/decay trends with ≥ 2 data points were including in population analysis 572 
as this methodology has been proven to maximally use sparse clinical data with drug 573 
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development55-56. All points were plotted and visualised. An ‘ascend’ or a ‘descend’ was 574 
defined according to the prevailing trend. A 20% alteration in direction was tolerated as part 575 
of the prevailing ascend or descend as appropriate. 576 
 577 
 578 
Structural model  579 
Structural model selection was performed for the most replete DABA dataset. Model fitting 580 
and selection was performed using previously published protocols for fitting clinical datasets 581 
as described below57-58. Briefly, linear regression (intercept close to 0, slope close to 1) was 582 
used to assess the goodness-of-fit of the observed/predicted values, the coefficient of 583 
determination of the linear regression and minimisation of log-likelihood, (Akaike Information 584 
Criterion) AIC and (Bayesian information criterion) BIC values were used for model selection.  585 
A change in BIC drop of >2 is generally considered to be significant; with 2-6 indicating 586 
positive evidence, 2-6 indicating positive-to-strong evidence, 6-10 indicating strong evidence 587 
and >10 indicating very strong evidence59.  588 
 589 
Further details of this analysis leading to the choice of models and analysis of the fit of models 590 
to data can be found in Supplementary Tables 3-4 and Extended data Figures 8-9. 591 
All chosen structural models showed strong to very strong evidence of describing the data the 592 
best out of the compared models. Two structural models were tested for antibody stimulation, 593 
a 1-compartmental stimulation model and a 1-compartmental model with saturable stimulation, 594 
based on the logistic growth model. The logistic growth model framework allows for 595 
plateauing antibody levels observed for a subset of stimulation profiles. For antibody decay, 596 
four structural models were tested; a 1-compartment decay model with first order elimination, 597 
a 2-compartment decay model with first order elimination from the central compartment and 598 
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the above two structural models with saturable recycling offsetting the endogenous elimination 599 
rate. 600 
 601 
Antibody stimulation was best modelled using the 1-compartmental model with saturable 602 




= 𝑘𝑔𝑟𝑜𝑤𝑡ℎ𝑋1 (1 −
𝑋1
𝐾𝑚𝑎𝑥
)    (Equation 1) 605 
 606 
Where X1, kgrowth and Kmax denoting antibody level in the compartment, the first order rate 607 
constant for endogenous antibody stimulation and the maximal antibody level at which 608 
stimulation plateaus, respectively. 609 
For antibody decay, the two-compartment decay model with saturable FcRn-dependent 610 
recycling (Equations. 2-4) as used to model antibody decay in multiple laboratory studies37 was 611 
found to best describe the data.  612 
𝑑𝑋1
𝑑𝑡




=  𝑘𝑐𝑝𝑋1 − 𝑘𝑝𝑐𝑋2     (Equation 3) 615 
 616 
𝑘𝑑𝑒𝑐𝑎𝑦 =  𝑘𝑒𝑛𝑑 −  (
𝑉𝑚𝑎𝑥
𝑋1+𝐾𝑚
)    (Equation 4) 617 
 618 
Where X1 and X2 are the antibody levels in the central and peripheral compartments. The rate 619 
constants kdecay, kcp and kpc denote the empirically observed antibody level dependent rate 620 
constant and the first order rate constants to and from the peripheral compartment. kdecay is in-621 
turn dependent on the endogenous decay rate kend which is offset by a antibody dependent 622 
saturable recycling rate described by a Michaelis-Menten term with parameters Vmax and Km 623 
denoting the maximal recycling rate and antibody level at which half the maximal recycling 624 
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rate occurs. The optimal structural models above were then used to model the more sparse nAb 625 
assay datasets allowing for comparability between DABA and nAb model parameters. 626 
Generally, individual predicted vs. observed value correlations were found to excellent (R2 627 
>0.8) and population predictions vs. observed values were good (R2 >0.6). 628 
 629 
Monte Carlo simulations were performed using Pmetrics as previously described57-58. Briefly, 630 
1000 individuals were randomly sampled from parameter distributions defined in the 631 
population models of antibody stimulation and decay. The interquartile range of modelled 632 
antibody levels was then plotted longitudinally for average starting antibody levels for decay 633 
and stimulation profiles (Fig. 3. c-h). 634 
 635 
With regard to the choice to model the stimulation and decay data separately: in principle, an 636 
immune response followed by a gradual return to baseline post-stimulus could be characterised 637 
by a single pharmacodynamic model. In the simplest form the dynamics can be described by a 638 
single compartmental model with the stimulus placed on the input rate and first order 639 
elimination, although more mechanistic models based on known pharmacology may also be 640 
appropriate if the data is of sufficient quality to estimate the unknown model components. In a 641 
controlled trial setting the onset of a stimulus event would be controlled and the subsequent 642 
immune response measured relative to this origin with sufficient frequency to capture the 643 
dynamics over time. In contrast, this study was observational with plasma samples taken 644 
intermittently that captured only part of the changing levels in the nAbs – either the growth or 645 
decay phase in most cases, but on occasion both. Given the lack of detectable viral load and 646 
the observational nature of the nAb response data, the ability to fit a single, integrated 647 
pharmacodynamic model to the data is limited. The most tractable solution in this case was to 648 
split the data into two groups and modelled separately: the first model quantifying the rate of 649 
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increase in nAbs and the second model describing the subsequent decay. The antibody decay 650 
was based on37. Whilst this 2-stage approach did not allow data from the “stimulation” phase 651 
to inform the model fit of the “decay” phase – and vice versa , it did enable an accurate and 652 
quantitative characterisation of both the stimulation and decay dynamics, which has not been 653 
characterised for EBOV disease prior to this study, and which may be used to inform future 654 
work in this area and other impactful viral diseases such as COVID-19. 655 
 656 
 Statistical Analysis  657 
Statistical analyses of data were implemented using GraphPad Prism 6.0 software. Unpaired 658 
sample comparisons were conducted for all data, however, individual figures state the 659 
corresponding statistical test performed. These include:  660 
- Parametric and non-parametric t-tests (student t-test and Mann-Whitney U test)  661 
- Parametric and non-parametric ANOVA (Ordinary ANOVA and Kruskal-Wallis test) 662 
P values were depicted by *: * P value < 0.05, ** P value < 0.01, *** P value < 0.001, **** P 663 
value < 0.0001. 664 
 665 
Data Availability 666 
All datasets generated during and/or analysed during the current study are available from the 667 
corresponding authors on reasonable request. 668 
 669 
References to the Methods 670 
44. Scott, J.T. and M.G. Semple, Ebola virus disease sequelae: a challenge that is not 671 
going away. The Lancet Infectious Diseases, 2017. 17(5): p. 470-471. 672 
45. Platt, E, J,, Bilska, M., Kozak, S.L., Kabat, D. & Montefiori, D. C. Evidence that 673 
ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the 674 
outcome of neutralizing antibody assays with human immunodeficiency virus type 1. 675 
J. Virol. 2009 83, 8289-92 (2009). 676 
30 
 
46. Takeuchi, Y., McClure, M.O. & Pizzato. M. Identification of γ-retroviruses 677 
constitutively released from cell lines used for HIV research. J. Virol. 82, 12585-678 
1258 (2008). 679 
47. Wei, X. et. al. Emergence of resistant human immunodeficiency virus type 1 in 680 
patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents 681 
Chemother 46, 1896-1905 (2002). 682 
48. Derdeyn, C.A. et.al. Sensitivity of human immunodeficiency virus type 1 to the 683 
fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop 684 
of gp120. J. Virol. 74, 8358-8367 (2000). 685 
49. Platt, E.J., Wehrly, K,, Kuhmann, S.E., Chesebro, B. & Kabat, D. Effects of CCR5 686 
and CD4 cell surface concentrations on infections by macrophagetropic isolates of 687 
human immunodeficiency virus type 1. J Virol 72, 2855-2864 (1998). 688 
50. Biek, R., Walsh, P. D., Leroy, E. M. & Real, L. A. A Real Recent Common Ancestry 689 
of Ebola Zaire Virus Found in a Bat Reservoir. PLoS Pathog. 2(10), e90 (2006). 690 
51. Connor, R. I., Chen, B. K., Choe, S. & Landau N. R. Vpr is required for efficient 691 
replication of human immunodeficiency virus type-1 in mononuclear phagocytes. 692 
Virology 206, 935–944 (1995). 693 
52. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 694 
(2003). 695 
53. Neely, M. N., van Guilder, M. G., Yamada, W. M., Schumitzky, A. & Jelliffe, R. W. 696 
Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and 697 
parametric pharmacometric modeling and simulation package for R. Ther. Drug 698 
Monit. 34, 467–476 (2012). 699 
54. R: A language and environment statistical computing. v. 3.1.0 (R Foundation for 700 
Statistical Computing, Vienna, Austria, 2014). 701 
55. De Cock, R. F. W. et. al. Role of modelling and simulation in Paediatric Clinical 702 
Research. Eur J Clin Pharmacol. 67,,S5–S16 (2011). 703 
56. Aarons, L. et al. Role of Modelling and Simulation in Phase I Drug Development. 704 
Eur. J. Pharm. Sci. 13, 115-122 (2001). 705 
57. Roberts, J. A. et al. Plasma and target-site subcutaneous tissue population 706 
pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill 707 
patients. J. Antimicrob. Chemother. 70, 1495-1502 (2015). 708 
31 
 
58. Grau, S, et al. Plasma and peritoneal fluid population pharmacokinetics of 709 
micafungin in post-surgical patients with severe peritonitis. J. Antimicrob. 710 
Chemother. 70, 2854–2861 (2015). 711 
59. Mould, D. and R. Upton, Basic Concepts in Population Modeling, Simulation, and 712 
Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic 713 
Modeling Methods. CPT: Pharmacometrics & Systems Pharmacology, 2013. 2(4): p. 714 
38. 715 
 716 
Acknowledgements  717 
We thank colleagues variously for their support and encouragement: the Sierra Leone 718 
Association of Ebola Survivors (Freetown, Sierra Leone); the members of the Convalescent 719 
Products and Allied Therapy Intervention Technical Committee; the Research Ethics 720 
Committee and the Pharmacy Board Committee (all Ministry of Health and Sanitation, 721 
Republic of Sierra Leone); staff in Virus Reference Department Public Health England 722 
(Colindale, England) for handling and clearing samples from quarantine; G. McCann and L. 723 
Matthews for project management (Institute of Translational Medicine and National Institute 724 
for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, 725 
University of Liverpool, Liverpool, UK); I. Bates’ expertise in strengthening transfusion 726 
services (Department of International Public Health, Liverpool School of Tropical Medicine, 727 
Liverpool, UK); W.A. Brooks (International Severe Acute Respiratory and Emerging Infection 728 
Consortium [ISARIC], International Centre for Diarrheal Disease Research, Dhaka, 729 
Bangladesh, and Department of International Health, Johns Hopkins University, Baltimore, 730 
MD); M.P. Kieny (World Health Organization, Geneva, Switzer-land); C. Burm and D. Arango 731 
(Clinical Trials Unit, Institute of Tropical Medicine, Antwerp, Belgium); and N.F. Walker 732 
(London School of Hygiene and Tropical Medicine). Ashley Jones of the University of 733 
Liverpool; colleagues from the World Health Organization (WHO); and the International 734 
Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). It is with affection 735 
32 
 
and sadness that we commemorate the passing on 5th July 2019 of Dr Samuel Baker, lately 736 
head National Safe Blood Service, Ministry of Health and Sanitation, Freetown, Sierra Leone. 737 
Proofreading support provided by Michel de Baar and graphical support provided by Suzanne 738 
Yee. 739 
 740 
Author Contributions  741 
GP, WAP, JTS and MGS initiated and designed the study. CA, RST, JTS, RJD and RG 742 
collected data and/or performed the analysis. CA, GP and WAP wrote the manuscript. MGS, 743 
JTS, GP, RST, RJD and WAP edited the manuscript. MGS sourced the funding and is Ebola-744 
CP Consortium Lead Investigator. All authors were critical for study delivery whether through 745 
recruitment, coordination, collection of participant data & material, assay development or 746 
analysis of samples. All authors read and approved the contents of the manuscript. Readers are 747 
welcome to comment on the online version of the paper. GSK was not involved in the design, 748 
conduct or analysis of the study. 749 
 750 
Competing interest declaration 751 
All authors have no conflicts of interest to declare 752 
 753 
Current affiliations 754 
Richard S Tedder, Division of Infectious Diseases, Imperial College London, UK. Catherine 755 
C Smith, Oxford Vaccine Group, University of Oxford, Centre for Clinical Vaccinology and 756 
Tropical Medicine, Oxford, UK. Christine P Cole, Royal Liverpool and Broadgreen University 757 
Hospitals NHS Trust, Liverpool UK. Janet T Scott, MRC-University of Glasgow Centre for 758 





Consortia Authors 762 
The Consortium Investigators and Collaborators for Ebola CP (Convalescent Plasma for Early 763 
Ebola Virus Disease in Sierra Leone) are: M.G. Semple (Consortium Lead Investigator) and 764 
J.T. Scott, (both Faculty of Health and Life Science & NIHR Health Protection Research Unit 765 
in Emerging and Zoonotic Infections University of Liverpool, Liverpool, UK); SM Gevao 766 
(Country Lead Investigator), F. Sahr (Country Deputy Lead Investigator), C.P. Cole and J. 767 
Russell (all College of Medicine and Allied Health Sciences, Freetown, Sierra Leone); S. 768 
Baker, O. Kargbo, and P. Kamara (all National Safe Blood Service, Connaught Hospital, 769 
Ministry of Health & Sanitation, Freetown, Sierra Leone); M. Lado and C.S. Brown (all King’s 770 
Sierra Leone Health Partnership, King’s Health Partners & King’s College London, London, 771 
UK); B. Conton (Physio Fitness Rehabilitation Centre, Freetown, Sierra Leone); J. van 772 
Griensven, R. Ravinetto and Y. Claeys (all Institute of Tropical Medicine, Antwerp, Belgium); 773 
R.S. Tedder, R. Gopal, and T.J.G. Brooks (National Infection Service, Public Health England, 774 
London, UK); C.C. Smith (Health Protection Scotland, UK); H.A. Doughty (NHS Blood and 775 
Trans-plant & College of Medical and Dental Sciences, University of Birmingham, 776 
Birmingham, UK); A. Mari Saez and M. Borchert (all Institute for Tropical Medicine and 777 
International Health, Charité, Berlin, Germany); A.H. Kelly (Department of Sociology, 778 
Philosophy and Anthropology, Exeter University, Exeter, UK); J.K. Baillie (The Roslin 779 
Institute, University of Edinburgh, Edinburgh, UK); N. Shindo, and D. Pfeifer (all Department 780 
of Pandemic and Epidemic Diseases, World Health Organization, Geneva, Switzerland); D.L. 781 
Hoover (ClinicalRM Inc., Hinckley, OH); W.A. Fischer II and D.A. Wohl (all Department of 782 
Medicine, University of North Carolina, Chapel Hill, NC); N.M. Thielman (Duke University 783 
School of Medicine, Durham, NC); P.W. Horby and L. Merson (all Nuffield Department of 784 
Medicine, University of Oxford, Oxford, UK); and P.G. Smith and T. Edwards (all Medical 785 
Research Council Tropical Epidemiology Group, London School of Hygiene &Tropical 786 
34 
 
Medicine, London, UK). The authors alone are responsible for the views expressed in this work 787 
and they do not necessarily represent the views, decisions or policies of the institutions with 788 
which they are affiliated. 789 
 790 
Funding 791 
The study “Convalescent plasma for early Ebola virus disease in Sierra Leone (Ebola CP)” 792 
(ISRCTN13990511 and PACTR201602001355272) was supported by the Wellcome Trust 793 
(Award 106491) and Bill and Melinda Gates Foundation; Public Health England Ebola 794 
Emergency Response; and the Blood Safety Programme, National Health Service Blood and 795 
Transplant. JTS was supported by the Wellcome Trust. MGS and JTS were supported by the 796 
UK National Institute for Health Research Health Protection Research Unit in Emerging and 797 
Zoonotic Infections at the University of Liverpool. The funders had no role in the collection 798 
and analysis of the samples, in the interpretation of data, in writing the report, nor in the 799 
decision to submit the paper for publication. 800 
 801 
Additional Information 802 
Supplementary information is available for this paper.  803 
Correspondence and requests for materials should be addressed to GP 804 
(g.pollakis@liverpool.ac.uk). 805 
 806 
Extended Data Figure legends  807 
Extended Data Fig. 1. (a) Variant pEBOV14-GP plasmid concentrations were transfected 808 
alongside 2000 ng of pSG3-HIV-1 backbone. The resulting pseudo-typed virus, quantified by 809 
a HIV-1-p24 capsid ELISA (squares), was tested for infectivity in TZM-bl cells as measured 810 
by luciferase activity (bars/mean value +-SD). The red marked square identifies the 811 
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glycoprotein concentrations that can be used in the assay. (b) Inhibition profiles with negative 812 
plasma donated from six individuals (grey squares), indicating no specific plasma inhibition 813 
during the neutralisation assay. All negative assays and plasmas were combined to define the 814 
range within which negative plasma control were acceptable (red squares) thus defining a valid 815 
assay. The blue line shows the lack of reactivity on the HIV-1-enveloped pseudo-typed virus 816 
by EBOV neutralizing convalescent plasma (CP) (squares and circles indicate the median and 817 
the vertical lines the standard error). (c) Neutralisation profiles of pEBOV14-GP by the WHO 818 
reference panel of anti-EBOV CP. The standard identifiers are shown. (d) Reproducibility of 819 
the neutralisation assay determined by measuring the IC50 of CP plasma on the three EBOV 820 
isolates (yellow-pEBOV14-GP, purple- pEBOV95-GP and green- pEBOV14m-GP). The two-821 
tailed parametric paired t test was used. (e) Neutralisation potential of CPs against three virus 822 
strains (pEBOV14-GP/n=83, pEBOV95-GP/n=69 and pEBOV14m-GP/n=77) expressed in 823 
IC70 (Data are presented as mean values +/- SD. Kruskal-Wallis test was performed). (f) delta-824 
IC70 neutralisation titres between virus strains pairs by each post-cure study participant. (g) 825 
Positive association between PPV IC70 titres the live virus plaque reduction neutralisation test 826 
(PRNT). (h) Positive association between PPV IC70 neutralisation titres and the double antigen 827 
bridging assay (DABA). 828 
 829 
Extended Data Fig. 2. (a) anti-EBOV14-GP (n=92), (b) anti-EBOV14m-GP (n=70) and (c) 830 
anti-EBOV95-GP (n=76) neutralisation curves using serial dilutions of CP inhibiting PPV cell 831 
entry, as described in methods. The plasma samples were deciphered as possessing low (blue), 832 
intermediate (magenta) or high (orange) neutralisation to demonstrate the similar profiles of 833 
the three virus glycoproteins studied. The red square curve indicates the range of inhibition by 834 
control plasma. (d) Comparison of the analyses (n=30) i) considering the 0% inhibition value 835 
whenever two reciprocal consecutive high plasma dilutions produced equal infection levels ii) 836 
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considering 0% inhibition as the infection values of virus in the absence of convalescent plasma 837 
performed in each individual experiment. The Pearson correlation coefficients were computed. 838 
 839 
Extended Data Fig. 3. Association of IC50 and IC70 neutralizing dilutions of the post-cure 840 
plasma samples inhibiting cell entry of pseudo-typed virus particles harbouring the variant 841 
EBOV GP molecules. The Pearson correlation coefficients were computed. 842 
 843 
Extended Data Fig. 4. Longitudinal post convalescence nAb variation in the plasma of 844 
individuals 18,19 and 21 demonstrated by pseudo-typed virus particle neutralisation. Anti-845 
EBOV14-GP (light blue) and anti- EBOV95-GP (dark blue) nAb titres were overlaid with the 846 
blocking EIAs carried out for the detection of antibody against the Nucleoprotein [NP] (brown 847 
squares), the viral matrix protein 40 [VP40] (purple squares) and the Glycoprotein [GP] (green 848 
squares)  849 
 850 
Extended Data Fig. 5. Longitudinal G-capture (pink) and competitive (green) EIAs performed 851 
using the plasma individuals 18, 19, 21, 45 and 49 against the Glycoprotein as described in 852 
Tedder et.al.(21) The antibody reactivities were overlaid with pseudo-typed virus particle IC50 853 
neutralisation values against  EBOV14-GP (light blue) and EBOV95-GP (dark blue). 854 
 855 
Extended Data Fig. 6. Total antibody reactivity as measured by double antigen bridging assay 856 
(DABA)(average of a duplicate measurement) for the Ebola post-cure cohort participants with 857 
longitudinal follow up (≥2 data points, n=51) demonstrating decline/re-stimulation/decline (in 858 
any order) of antibody reactivity over-time. Decline is indicated by a black line and re-859 




Extended Data Fig. 7. Total antibody reactivity as measured by double antigen bridging assay 862 
(DABA). ‘Lowest titre following decline’ is the last point in a participant presenting antibody 863 
titres decline while ‘High titre upon stimulation’ is the subsequent point demonstrating 864 
antibody stimulation, Two-tailed parametric paired t-test (p=0.0014). 865 
 866 
Extended Data Fig. 8. Observed versus predicted plots for selected logistic growth model for 867 
antibody stimulation, as determined by the DABA assay: (a) population predicted values (b) 868 
individual predicted values. Observed versus predicted plots for selected 2 compartment decay 869 
model with saturable recycling for antibody stimulation, as determined by the DABA assay: 870 
(c) population predicted values (d) individual predicted values. Solid red circles represent the 871 
individual observed/model-predicted Ab values. Solid blue line and dotted red line represents 872 
the line of regression and line of unity, respectively. 873 
 874 
Extended Data Fig. 9 Flow diagram describing the observed antibody decrease and increase 875 
events as measured by DABA, which are used to develop the compartmental population 876 
pharmacodynamic models. 877 
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